Scarica l'app Stockscreener
5.47
2.84%
-0.16
Precedente Chiudi:
$5.63
Aprire:
$5.63
Volume 24 ore:
118.15K
Relative Volume:
0.25
Capitalizzazione di mercato:
$41.96M
Reddito:
$52.29M
Utile/perdita netta:
$-73.52M
Rapporto P/E:
-8.2879
EPS:
-0.66
Flusso di cassa netto:
$-100.45M
1 W Prestazione:
+6.21%
1M Prestazione:
+7.68%
6M Prestazione:
-43.55%
1 anno Prestazione:
-58.84%
Intervallo 1D:
$5.25
$5.63
Intervallo di 1 settimana:
$5.25
$6.10
Portata 52W:
$3.61
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Nome
Precision Biosciences Inc
Settore
Industria
Telefono
919-314-5512
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Confronta DTIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.47 | 41.96M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Iniziato | Guggenheim | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-09 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Ripresa | BTIG Research | Buy |
| 2020-04-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-05 | Iniziato | Stifel | Buy |
| 2020-02-25 | Iniziato | William Blair | Outperform |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-22 | Iniziato | Barclays | Overweight |
| 2019-04-22 | Iniziato | Goldman | Buy |
| 2019-04-22 | Iniziato | JP Morgan | Overweight |
| 2019-04-22 | Iniziato | Jefferies | Buy |
Mostra tutto
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Long Term Trading Analysis for (DTIL) - Stock Traders Daily
Can This New Gene Editing Approach Transform Duchenne Muscular Dystrophy Treatment? - StockTitan
Precision BioSciences (DTIL) Stock Price, News & Analysis - MarketBeat
H.C. Wainwright Maintains Buy on Precision BioSciences Stock By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Buy on Precision BioSciences Stock - Investing.com India
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV - Yahoo Finance
Precision BioSciences’ (DTIL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate - AOL
Breakthrough in Hepatitis B Treatment: Precision BioSciences’ New Hope - Jomfruland.net
Precision Biosciences chief research officer sells $49,274 in stock - MSN
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial - BioSpace
Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha
Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv - Marketscreener.com
Revolutionary Gene Therapy Achieves First-Ever ARCUS Success Against Hepatitis BWhat's Next? - StockTitan
Precision Biosciences' general counsel sells shares worth $42,765 - MSN
Precision BioSciences announces board member's retirement - MSN
Precision BioSciences (DTIL) Poised for Growth with ARCUS Technology and Strategic Partnerships - HPBL
Precision BioSciences announces board member's retirement By Investing.com - Investing.com Canada
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs - BioSpace
Precision BioSciences’ Cassie Gorsuch, PhD named CSO - TipRanks
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Precision Bio rises after gene editing data: BMO upgrades (update) - MSN
Precision Biosciences' general counsel sells shares worth $42,765 By Investing.com - Investing.com Canada
Precision Biosciences chief research officer sells $49,274 in stock By Investing.com - Investing.com Canada
Precision Biosciences Inc Azioni (DTIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):